Simone Bier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Simone Bier has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Arnulf Stenzl
Department of Urology, Eberhard-Karls-University, 72074 Tuebingen, Germany
3 shared publications Christian Schwentner
Department of Urology, Eberhard Karls University, Tuebingen, Germany
2 shared publicationsJörg Hennenlotter
Department of Urology, Eberhard Karls University, Tuebingen, Germany
2 shared publications- Maria Schubert
Department of Andrology Centre of Reproductive Medicine and Andrology (CeRA) University Hospital of Münster Münster Germany
2 shared publications - Mattia Anfosso
Department of Andrology Centre of Reproductive Medicine and Andrology (CeRA) University Hospital of Münster Münster Germany
2 shared publications Michael Esser
Department of Urology, Eberhard Karls University, Tuebingen, Germany
2 shared publications
Latest Publications
- Open Access
Can Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non‐Obstructive Azoospermia?
Background: Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates (SRR) at microdissection testicular sperm extraction (mTESE), although evidence remains controversial and meta‐analyses have not shown consistent benefit. Aims: To determine whether FpHT improves SRR in hypogonadal men with NOA undergoing mTESE. Methods: We retrospectively evaluated 1256 selected men with NOA (601 Klinefelter syndrome [KS], 655 normal karyotype) from a cohort of 3086 men who underwent mTESE at our tertiary andrology center between 2010 and 2024. Patients with obstructive azoospermia, prior gonadotoxic exposure, or hypogonadotropic hypogonadism were excluded. All participants underwent comprehensive clinical, hormonal, and genetic assessment. Comparisons were performed between eugonadal and hypogonadal patients, and within the hypogonadal group, between those who received FpHT and those who did not. Results: Hypogonadism was present in 49.9% of patients, predominantly in KS ( p < 0.001). FpHT significantly increased serum T levels in both groups (ΔT +3.1 nmol/L in KS; +5.6 nmol/L in 46, XY; p < 0.001). However, despite biochemical normalization, FpHT did not improve SRR in either karyotypic group (overall SRR: 32.4%). Multivariate analysis identified younger age as the sole independent predictor of successful retrieval in KS ( p = 0.011). Conclusion: FpHT restores serum androgen levels but does not improve spermatogenic activity or sperm retrieval rates in men with NOA. These findings support current EAU guidelines and indicate that FpHT should be used to treat symptomatic hypogonadism rather than to enhance fertility outcomes before mTESE.
Open AccessCan Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non‐Obstructive Azoospermia?
Background: Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates (SRR) at microdissection testicular sperm extraction (mTESE), although evidence remains controversial and meta‐analyses have not shown consistent benefit. Aims: To determine whether FpHT improves SRR in hypogonadal men with NOA undergoing mTESE. Methods: We retrospectively evaluated 1256 selected men with NOA (601 Klinefelter syndrome [KS], 655 normal karyotype) from a cohort of 3086 men who underwent mTESE at our tertiary andrology center between 2010 and 2024. Patients with obstructive azoospermia, prior gonadotoxic exposure, or hypogonadotropic hypogonadism were excluded. All participants underwent comprehensive clinical, hormonal, and genetic assessment. Comparisons were performed between eugonadal and hypogonadal patients, and within the hypogonadal group, between those who received FpHT and those who did not. Results: Hypogonadism was present in 49.9% of patients, predominantly in KS ( p < 0.001). FpHT significantly increased serum T levels in both groups (ΔT +3.1 nmol/L in KS; +5.6 nmol/L in 46, XY; p < 0.001). However, despite biochemical normalization, FpHT did not improve SRR in either karyotypic group (overall SRR: 32.4%). Multivariate analysis identified younger age as the sole independent predictor of successful retrieval in KS ( p = 0.011). Conclusion: FpHT restores serum androgen levels but does not improve spermatogenic activity or sperm retrieval rates in men with NOA. These findings support current EAU guidelines and indicate that FpHT should be used to treat symptomatic hypogonadism rather than to enhance fertility outcomes before mTESE.
- Open Access
- 30 January 2018
- Published by Wiley in Disease Markers
- Vol. 2018, 1-5
Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
Objectives. To assess the performance of urine markers determined in urine samples from the bladder compared to samples collected from the upper urinary tract (UUT) for diagnosis of UUT urothelial carcinoma (UC). Patients and Methods. The study comprised 758 urine samples either collected from the bladder () or UUT (). All patients underwent urethrocystoscopy and UUT imaging or ureterorenoscopy. Cytology, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and nuclear matrix protein 22 (NMP22) were performed. Results. UUT UC was diagnosed in 59 patients (19.1%) (UUT urine) and 27 patients (7.2%) (bladder-derived urine). For UUT-derived samples, sensitivities for cytology, FISH, NMP22, and uCyt+ were 74.6, 79.0, 100.0, and 100.0, while specificities were 66.6, 50.7, 5.9, and 66.7%, respectively. In bladder-derived samples, sensitivities were 59.3, 52.9, 62.5, and 50.0% whereas specificities were 82.9, 85.0, 31.3, and 69.8%. In UUT-derived samples, concomitant bladder cancer led to increased false-positive rates of cytology and FISH. Conclusions. Urine markers determined in urine collected from the UUT exhibit better sensitivity but lower specificity compared to markers determined in bladder-derived urine. Concomitant or recent diagnosis of UC of the bladder can further influence markers determined in UUT urine.- 30 January 2018
- Published by Wiley in Disease Markers
- Vol. 2018, 1-5
Open AccessPerformance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
Objectives. To assess the performance of urine markers determined in urine samples from the bladder compared to samples collected from the upper urinary tract (UUT) for diagnosis of UUT urothelial carcinoma (UC). Patients and Methods. The study comprised 758 urine samples either collected from the bladder () or UUT (). All patients underwent urethrocystoscopy and UUT imaging or ureterorenoscopy. Cytology, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and nuclear matrix protein 22 (NMP22) were performed. Results. UUT UC was diagnosed in 59 patients (19.1%) (UUT urine) and 27 patients (7.2%) (bladder-derived urine). For UUT-derived samples, sensitivities for cytology, FISH, NMP22, and uCyt+ were 74.6, 79.0, 100.0, and 100.0, while specificities were 66.6, 50.7, 5.9, and 66.7%, respectively. In bladder-derived samples, sensitivities were 59.3, 52.9, 62.5, and 50.0% whereas specificities were 82.9, 85.0, 31.3, and 69.8%. In UUT-derived samples, concomitant bladder cancer led to increased false-positive rates of cytology and FISH. Conclusions. Urine markers determined in urine collected from the UUT exhibit better sensitivity but lower specificity compared to markers determined in bladder-derived urine. Concomitant or recent diagnosis of UC of the bladder can further influence markers determined in UUT urine. - 24 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1528-e1529
Expression of tumor progression-associated genes in circulating tumor cells of patients with different stages of prostate cancer
- 24 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1528-e1529
Expression of tumor progression-associated genes in circulating tumor cells of patients with different stages of prostate cancer
- Open Access
- 22 December 2014
- Published by Wiley in Disease Markers
- Vol. 2014, 1-7
Stepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer
Background. The optimal use of urine markers in the surveillance of non-muscle-invasive bladder cancer (NMIBC) remains unclear. Aim of the present study was to investigate the combined and stepwise use of the four most broadly available urine markers to detect tumor recurrence in patients undergoing surveillance of NMIBC.Patients and Methods. 483 patients with history of NMIBC were included. Cytology, UroVysion, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and NMP22 ELISA were performed before surveillance cystoscopy. Characteristics of single tests and combinations were assessed by contingency analysis.Results. 128 (26.5%) patients had evidence of tumor recurrence. Sensitivities and negative predictive values (NPVs) of the single tests ranged between 66.4–74.3 and 82.3–88.2%. Two-marker combinations showed sensitivities and NPVs of 80.5–89.8 and 89.5–91.2%. A stepwise application of the two-test combinations with highest accuracy (cytology and FISH; cytology and uCyt+; uCyt+ and FISH) showed NPVs for high-risk recurrences (G3/Cis/pT1) of 98.8, 98.8, and 99.1%, respectively.Conclusions. Combinations of cytology, FISH, immunocytology, and NMP22 show remarkable detection rates for recurrent NMIBC. Stepwise two-test combinations of cytology, FISH, and immunocytology have a low probability of missing a high-risk tumor. The high sensitivities may justify the use of these combinations in prospective studies assessing the use of urine markers to individualize intervals between cystoscopies during follow-up.
- 22 December 2014
- Published by Wiley in Disease Markers
- Vol. 2014, 1-7
Open AccessStepwise Application of Urine Markers to Detect Tumor Recurrence in Patients Undergoing Surveillance for Non-Muscle-Invasive Bladder Cancer
Background. The optimal use of urine markers in the surveillance of non-muscle-invasive bladder cancer (NMIBC) remains unclear. Aim of the present study was to investigate the combined and stepwise use of the four most broadly available urine markers to detect tumor recurrence in patients undergoing surveillance of NMIBC.Patients and Methods. 483 patients with history of NMIBC were included. Cytology, UroVysion, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and NMP22 ELISA were performed before surveillance cystoscopy. Characteristics of single tests and combinations were assessed by contingency analysis.Results. 128 (26.5%) patients had evidence of tumor recurrence. Sensitivities and negative predictive values (NPVs) of the single tests ranged between 66.4–74.3 and 82.3–88.2%. Two-marker combinations showed sensitivities and NPVs of 80.5–89.8 and 89.5–91.2%. A stepwise application of the two-test combinations with highest accuracy (cytology and FISH; cytology and uCyt+; uCyt+ and FISH) showed NPVs for high-risk recurrences (G3/Cis/pT1) of 98.8, 98.8, and 99.1%, respectively.Conclusions. Combinations of cytology, FISH, immunocytology, and NMP22 show remarkable detection rates for recurrent NMIBC. Stepwise two-test combinations of cytology, FISH, and immunocytology have a low probability of missing a high-risk tumor. The high sensitivities may justify the use of these combinations in prospective studies assessing the use of urine markers to individualize intervals between cystoscopies during follow-up.